Masakazu Toi

TL;DR: Investigation of the different efficacies of various AIs, the optimal dosing period, and suitable combination with adjuvant chemotherapy will enable breast cancer drug therapy to be individualized to suit each patient's condition.

TL;DR: One year of PAL added to ET is not cost-effective in women with residual invasive disease after NACT in Germany, and findings were robust in the scenarios evaluated.

TL;DR: In this article, latest knowledge regarding breast cancer genome, especially in terms of 'evolution', is summarized.

TL;DR: In this article, the problem of obtaining a vaccine containing a specific cell growth factor (segment), which is excellent in suppressing action on arterialization which participates in proliferation, infiltration and transfer of a solid cancer and useful for treatment of various kinds of diseases including cancer and suppression of onset thereof, is addressed.

TL;DR: It is suggested that a temporary blood pressure drop after bevacizumab administration could be a predictive marker for bevacsizumabs treatment.